Correlation Engine 2.0
Clear Search sequence regions

  • humans (1)
  • isoforms (2)
  • LDH (11)
  • patients (1)
  • poor prognosis (2)
  • prognosis (1)
  • serum (5)
  • tumour burden (2)
  • Sizes of these terms reflect their relevance to your search.

    High serum lactate dehydrogenase (LDH) levels are typically associated with a poor prognosis in many cancer types. Even the most effective drugs, which have radically improved outcomes in patients with melanoma over the past decade, provide only marginal benefit to those with high serum LDH levels. When viewed separately from the oncological, biochemical, biological and immunological perspectives, serum LDH is often interpreted in very different ways. Oncologists usually see high serum LDH only as a robust biomarker of a poor prognosis, and biochemists are aware of the complexity of the various LDH isoforms and of their key roles in cancer metabolism, whereas LDH is typically considered to be oncogenic and/or immunosuppressive by cancer biologists and immunologists. Integrating these various viewpoints shows that the regulation of the five LDH isoforms, and their enzymatic and non-enzymatic functions is closely related to key oncological processes. In this Review, we highlight that serum LDH is far more than a simple indicator of tumour burden; it is a complex biomarker associated with the activation of several oncogenic signalling pathways as well as with the metabolic activity, invasiveness and immunogenicity of many tumours, and constitutes an extremely attractive target for cancer therapy. © 2022. Springer Nature Limited.


    Giuseppina Claps, Sara Faouzi, Virginie Quidville, Feras Chehade, Shensi Shen, Stéphan Vagner, Caroline Robert. The multiple roles of LDH in cancer. Nature reviews. Clinical oncology. 2022 Dec;19(12):749-762

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36207413

    View Full Text